JSE-listed pharmaceuticals manufacturer Adcock Ingram says it has delivered a “resilient performance” for the six months ended December 31, 2023, despite challenges facing consumers, such as high interest rates, exchange rate depreciation, high inflation and loadshedding, which, consequently, result in lower disposable income. The group achieved an increase in turnover of 1% to R4.7-billion for the six- month period. Turnover grew in the consumer and hospital divisions, but was flat in the prescription and over-the-counter (OTC) divisions.
